Dyne Therapeutics (NASDAQ:DYN – Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.02, Zacks reports.
Dyne Therapeutics Price Performance
Shares of NASDAQ DYN traded up $0.57 during midday trading on Tuesday, reaching $43.64. 962,248 shares of the stock traded hands, compared to its average volume of 1,591,091. The company’s 50 day moving average is $37.89 and its 200 day moving average is $30.32. Dyne Therapeutics has a one year low of $6.40 and a one year high of $45.46. The stock has a market capitalization of $3.81 billion, a PE ratio of -10.77 and a beta of 1.07.
Insider Buying and Selling
In related news, insider Oxana Beskrovnaya sold 2,705 shares of the stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $28.27, for a total value of $76,470.35. Following the completion of the transaction, the insider now owns 149,647 shares of the company’s stock, valued at approximately $4,230,520.69. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, COO Susanna Gatti High sold 2,738 shares of the firm’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $28.27, for a total value of $77,403.26. Following the completion of the sale, the chief operating officer now owns 154,062 shares in the company, valued at approximately $4,355,332.74. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Oxana Beskrovnaya sold 2,705 shares of the company’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $28.27, for a total transaction of $76,470.35. Following the transaction, the insider now owns 149,647 shares in the company, valued at $4,230,520.69. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 202,133 shares of company stock worth $6,500,387. Insiders own 20.77% of the company’s stock.
Wall Street Analysts Forecast Growth
Read Our Latest Stock Analysis on DYN
About Dyne Therapeutics
Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Featured Articles
- Five stocks we like better than Dyne Therapeutics
- How to Invest in Tech StocksĀ and Top Tech Stocks to Consider
- Buy On Holdings Stock Before the Market Catches Its Second Wind?
- What is Short Interest? How to Use It
- 3 High-Potential Stocks That Could Turn Into Multi-Baggers
- Canadian Penny Stocks: Can They Make You Rich?
- CEO Swap: Starbucks Surges 22% on Hiring New CEO From Chipotle
Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.